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Abstract
Background: Vasodilatory function of radial artery (RA) declines following the transradial 
catheterization. However, it is uncertain whether impaired vasodilatory function develops in 
every patient. The aim of this study was to investigate the incidence and predictive factors of 
impaired vasodilatory function following transradial procedures.
Methods: Consecutive patients undergoing elective transradial procedures were prospec-
tively enrolled. Ultrasound examination of RA was recorded just before and 1 week after the 
procedure. RA diameters and flow velocities were measured at baseline, after flow mediated 
vasodilation (FMD) and after nitrate mediated vasodilation (NMD).
Results: Fifty-one patients were included (62 ± 11 years, 55% male, 41% hypertensive, 20% 
diabetic, 65% with coronary artery disease). Overall FMD and NMD were significantly im-
paired after 1 week. However, deterioration of FMD and NMD was observed in 67% and 71% of 
patients, respectively. Absolute change in FMD was significantly different in patients using a re-
nin–angiotensin system (RAS) inhibitor compared to those who were not (1.9 ± 12.9 vs. –7.7 ±  
± 12.7%, respectively, p = 0.025). Additionally, there was a moderate but significant correla-
tion between baseline RA diameter and absolute change in NMD (r = 0.419, p < 0.001). RAS 
blockade was independently associated with protection against FMD deterioration (OR 0.241, 
95% CI 0.066–0.883, p = 0.032), whereas RA diameter (OR 0.079, 95% CI 0.009–0.720,  
p = 0.024) and procedure time (OR 1.156, 95% CI 0.989–1.350, p = 0.068) were associated 
with NMD deterioration, although the latter had borderline significance.
Conclusions: Vasodilatory function of RA gets impaired in most patients following transra-
dial procedures. RAS blockade seems to exert a protective role against deteriorating endothe-
lium-dependent vasodilation, whereas smaller RA diameter and potentially longer procedure 
time are associated with impaired endothelium-independent vasodilation. (Cardiol J 2016; 
23, 1: 64–70)
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Introduction
Transradial approach improves patient comfort 
and clinical outcomes [1]. However, it is associ-
ated with morphological and functional changes 
in radial artery (RA) which may lead to occlusion. 
Previous studies with intravascular ultrasound, 
optical coherence tomography and histological 
examination revealed that intimal hyperplasia or 
intima-media thickening, peri-arterial tissue or fat 
necrosis and adventitial inflammation was evident 
in previously catheterized RA [2–6]. Vasodilator 
function of RA following transradial procedures was 
studied extensively as well, most studies reporting 
a decline in endothelium-dependent or independ-
ent vasodilation in acute phase followed by some 
recovery in long-term [6–13]. It is uncertain, how-
ever, whether vasodilatory function gets impaired 
in every patient or not. Therefore, the aim of this 
study was to find out the incidence and predictive 
factors of impaired vasodilatory function following 
transradial procedures.
Methods
The study was a single-center longitudinal 
observational trial. Consecutive patients over 
18 years old undergoing elective transradial pro-
cedure were prospectively enrolled. Exclusion 
criteria were i) emergency procedures, ii) patients 
with previous a procedure from the same RA 
(if contralateral RA cannot be used), iii) patients 
unwilling to participate. The study was conducted 
according to the Declaration of Helsinki — ethical 
principles for medical research involving human 
subjects [14]. All patients participating in the study 
gave their written informed consent. The study 
was approved by the Ethics Committee on Human 
Research, Faculty of Medicine, Kocaeli University, 
Turkey (KOÜ KAEK 2015/113).
Right RA was used as the first choice through-
out the study. Left RA was used in case of negative 
modified Allen’s test, previous coronary artery 
bypass grafting, or previous use of right RA. After 
subcutaneous injection of prilocaine, RA was punc-
tured with a 21 G needle and a 0.021’ guidewire. 
After skin incision, 10 cm 6 F hydrophilic coated 
sheath (Radifocus, Terumo Corp.) was introduced 
into the artery. Intra-arterial nitroglycerin (200 mg) 
was injected through the sheath for spasm prophy-
laxis. Procedures were performed with 5 F diag-
nostic catheters (Optitorque, Terumo Corp.) or 
6 F standard coronary guiding catheters (Launcher, 
Medtronic Inc.). Unfractionated heparin (5000 IU) 
was injected through diagnostic catheter into 
the ascending aorta. RA spasm was defined as 
marked forearm pain with resistance to catheter 
movements or sheath removal. Hemostasis was 
achieved with a simple gauze and compression 
technique without any special equipment (such 
as inflatable wrist band, etc.). Procedure time was 
measured from the time of sheath insertion to 
sheath removal at the end of the procedure. RA 
occlusion was evaluated with Doppler examina-
tion and defined as the absence of antegrade flow 
in RA. Transradial procedures were performed by 
experienced interventional cardiologists who use 
RA as default arterial access site.
Ultrasound examinations were recorded at 
morning hours of the procedure day and follow-up 
day (at 1 week) in a quiet, temperature controlled 
and dim room. Ultrasound images were recorded 
on a hard drive of a high resolution ultrasound 
unit (Vivid S5, GE Health Care) with 4–13 MHz 
linear array probe. Patients were instructed to 
fast and abstain from caffeine, alcohol and tobacco 
for at least 12 h before the examination. Medical 
treatment of patients was not withheld before 
baseline and follow-up examinations. Patients 
rested in supine position for approximately 20 min 
before evaluation. Vascular probe was located 
2–3 cm above puncture point for the evaluation 
of sheath injury.
Standard examination measurements were 
RA diameters and flow velocities at baseline, after 
brachial artery occlusion and after nitroglycerin 
administration before and 1 week after the proce-
dure. Longitudinal images were preferred for the 
measurement of RA diameter. Flow velocities were 
acquired after necessary angle correction and with 
sample volume located at the center of artery. After 
baseline images were recorded, blood pressure cuff 
located above elbow was inflated to suprasystolic 
pressure for 5 min. Highest hyperemic diameter 
and flow velocity was scanned between 30 s to 
2 min after cuff deflation, which were generally 
observed after 45–60 s. At least a 10 min break 
was kept between flow mediated dilatation (FMD) 
and nitrate mediated dilation (NMD) examinations. 
A single dose (400 mg) of nitroglycerin in commer-
cially available spray form was given orally. High-
est diameter and flow velocity of RA was scanned 
between 3 and 4 min of nitroglycerin application. 
Ultrasound examinations were performed and 
analyzed offline by a single cardiologist blinded to 
clinical data of the patients.
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Statistical analysis
Continuous data were presented as means ± stan- 
dard deviations or medians (interquartile ranges) 
depending on normality of distribution. Paired 
samples t-test or Wilcoxon signed-rank test was 
used for comparison of pre- and post-procedural 
ultrasound findings. T-test or Mann-Whitney U test 
was used for comparison of continuous data of two 
separate populations. Categorical variables were 
presented as numbers (percentages) and compared 
with c2 or Fisher’s exact test. Correlations between 
two variables was tested with Pearson test. Lo-
gistic regression analysis was used to determine 
independent variables associated with RA injury. 
Results were tabulated as odds ratios (OR) and 
95% confidence intervals (CI). A two sided p value 
< 0.05 was considered significant. Data collec-
tion and analysis were performed using Statisti-
cal Package for the Social Sciences, version 11.0 
(SPSS Inc.).
Results
Fifty-two consecutive patients were prospec-
tively included. One patient declined to attend 
follow-up visit and was excluded from analysis. The 
majority of procedures were performed through 
right RA (Table 1). There was only one access 
site crossover which was due to severe spasm; the 
patient was not excluded from the study. Two out 
of three procedures were completed with a single 
catheter. Again approximately two thirds of patients 
were found to have coronary artery disease.
At follow-up, 4 patients were found to have 
RA occlusion. These were considered RA-injured 
patients and included in the analysis as impaired 
vasodilatory function. Mean diameter of RA was 
2.49 mm (range 1.7–3.2) and 71% of participants 
had RA diameter smaller than outer diameter of 
6 F sheath (Table 2). RA diameter significantly 
increased 1 week after transradial procedure, while 
the flow did not change significantly. In a similar 
manner, hyperemic and nitrate-mediate diameters 
increased significantly compared to pre-procedural 
findings and again flow velocities did not differ. 
Median FMD of the study was 15.3% and median 
NMD was 8.6%. These values significantly de-
creased after 1 week.
Figure 1 represents the distribution of abso-
lute change in FMD and NMD in study patients. 
Considering negative values a deterioration, 67% 
and 71% of study participants were found to have 
impaired RA vasodilatory function at 1 week. Al-
ternatively, both FMD and NMD were impaired in 
28 (55%) patients, and either FMD or NMD was 
impaired in 42 (82%) patients.
We compared patients with impaired vasodila-
tory functions with those with preserved vasodi-
latory functions (Table 3). Somewhat expectedly, 
Table 1. Baseline data. 
Demographics
Age [years] 62 ± 11
Male sex 28 (55%)
Hypertension 21 (41%)
Diabetes 10 (20%)
Hyperlipidemia (%) 8 (16%)
Smoker [%] 6 (12%)
Weight [kg] 75 ± 12
Height [m] 1.63 ± 0.07
Body mass index [kg/m2] 28.3 ± 5.2
Previous PCI 7 (14%)
Previous CABG 6 (12%)
Medications
Antiplatelet 43 (84%)
ACEI 9 (18%)
ARB 5 (10%)
Beta-blocker 34 (67%)
Calcium channel blocker 2 (3.9%)
Diuretic 4 (7.8%)
Statin 13 (26%)
Oral anti-diabetic 3 (5.9%)
Insulin 3 (5.9%)
Procedural findings
Right radial artery 44 (86%)
Diagnostic angiography 40 (78%)
PCI 11 (22%)
Procedure time [min] 8.2 (7–12)
Number of catheters used:
1 34 (67%)
2 15 (30%)
3 2 (3.9%)
Radial artery spasm 7 (14%)
Access site crossover 1 (2.0%)
Coronary artery disease:
Nonexistent 18 (35%)
Single vessel disease 19 (37%)
Multivessel disease 14 (28%)
Radial artery occlusion 4 (7.8%)
ACEI — angiotensin converting enzyme inhibitor; ARB — angioten-
sin receptor blocker; CABG — coronary artery bypass grafting;  
PCI — percutaneous coronary intervention
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FMD was impaired more frequently in patients with 
relatively high pre-procedural values, however 
baseline RA diameter was not different between 
two groups. Impaired FMD was observed signifi-
cantly less in patients using a renin–angiotensin 
system (RAS) inhibitor that is angiotensin con-
verting enzyme inhibitor (ACEI) or angiotensin 
receptor blocker (ARB). Additionally, hypertension 
tended to be less frequent in impaired FMD group. 
Like FMD, NMD was impaired more frequently 
in patients with high pre-procedural values while 
RA diameter was marginally smaller in impaired 
NMD groups. Median procedure time was signifi-
cantly longer in impaired group compared to the 
preserved group.
Logistic regression analyses were performed 
to find out independent predictors of deteriorating 
RA function. Both models included variables age, 
sex, body mass index, hypertension, diabetes, 
smoking, presence of coronary artery disease and 
those variables with a p value < 0.100 in univariate 
analysis (RAS inhibitor use for FMD, procedure 
time and baseline RA diameter for NMD). Mean 
accuracy of the models were 77% and 75% for the 
impairment in FMD and NMD, respectively.
Multivariate analyses revealed that treatment 
with any RAS inhibitor was independently associ-
ated with less RA injury assessed with FMD (OR 
0.241, 95% CI 0.066–0.883, p = 0.032). On the 
other hand, smaller RA diameter (OR 0.079, 95% 
CI 0.009–0.720, p = 0.024) and potentially longer 
procedure time (OR 1.156, 95% CI 0.989–1.350, 
p = 0.068) were associated with more RA injury as-
sessed with NMD, though the latter had borderline 
statistical significance.
Effects of RAS blockade and baseline RA diam-
eter on change in FMD and NMD were depicted in 
Figures 2 and 3. There was a moderate but signifi-
cant correlation between baseline RA diameter and 
absolute change in NMD (r = 0.419, p < 0.001). 
Table 2. Ultrasound assessment of radial artery.
Pre-procedure At 1 week P
Baseline diameter [mm] 2.49 ± 0.36 2.84 ± 0.30 < 0.001
Baseline flow [cm/s] 68 ± 20 63 ± 23 0.065
Hyperemia diameter [mm] 2.84 ± 0.41 3.11 ± 0.36 < 0.001
Hyperemia flow [cm/s] 80 ± 25 81 ± 28 0.899
Nitrate mediated diameter [mm] 2.78 ± 0.41 3.05 ± 0.37 < 0.001
Nitrate mediated flow [cm/s] 72 ± 21 71 ± 28 0.668
Flow mediated dilation [%] 15.3 (5.9–18.5) 10.3 (3.4–16.1) 0.019
Nitrate mediated dilation [%] 8.6 (4.5–17.9) 6.9 (3.3–11.5) 0.005
Figure 1. Distributions of absolute change in flow mediated dilation (FMD) (A) and nitrate mediated dilation (NMD) (B).
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Figure 2. Scatter dot plot of change in nitrate mediated 
dilation (NMD) vs. baseline radial artery (RA) diameter.
Table 3. Comparison of patients with preserved and impaired vasodilation.
FMD NMD
Preserved  
(n = 17)
Impaired  
(n = 34)
P Preserved  
(n = 15)
Impaired  
(n = 36)
P
Age [years] 61 ±10 63 ±11 0.672 62 ±10 62 ±11 0.933
Male sex 9 (53%) 19 (56%) 0.842 9 (60%) 19 (53%) 0.637
Weight [kg] 75 ± 14 75 ± 11 0.928 77 ± 11 74 ± 12 0.411
Height [m] 1.63 ± 0.08 1.64 ± 0.07 0.510 1.64 ± 0.07 1.63 ± 0.07 0.801
Body mass index [kg/m2] 28.8 ± 6.4 28.1 ± 4.5 0.627 29.0 ± 4.9 28.0 ± 5.3 0.566
Hypertension 10 (59%) 11 (33%) 0.070 6 (40%) 15 (42%) 0.912
Diabetes 5 (29%) 5 (15%) 0.270 3 (20%) 7 (19%) 0.964
Hyperlipidemia 2 (12%) 6 (18%) 0.703 1 (6.7%) 7 (19%) 0.409
Smoker 2 (12%) 4 (12%) 1.000 2 (13%) 4 (11%) 1.000
Antiplatelet 15 (88%) 28 (82%) 0.586 13 (87%) 30 (83%) 0.766
RAS inhibitor 8 (47%) 6 (18%) 0.027 5 (33%) 9 (25%) 0.543
Beta-blocker 13 (77%) 21 (62%) 0.294 11 (73%) 23 (64%) 0.514
Statin 5 (29%) 8 (24%) 0.738 3 (20%) 10 (28%) 0.730
Creatinine [mg/dL] 0.87 (0.76–1.14) 0.89 (0.76–1.0) 0.772 0.89 (0.75–1.1) 0.87 (0.78–1.0) 0.860
Hemoglobin [g/dL] 13.3 ±2.4 13.7 ± 1.9 0.524 13.3 ± 2.4 13.7 ± 1.9 0.576
Platelets [103/mL] 212 ± 52 214 ± 45 0.906 215 ± 53 212 ± 45 0.821
LDL [mg/dL] 123 ± 49 127 ± 42 0.737 129 ± 52 125 ± 41 0.731
HDL [mg/dL] 39 ± 7 39 ± 7 0.925 38 ± 7 40 ±7 0.559
Triglycerides [mg/dL] 131 (88–185) 165 (122–218) 0.114 142 (119–211) 152 (121–218) 0.901
Procedure type: PCI 2 (12%) 9 (27%) 0.297 2 (13%) 9 (25%) 0.472
Procedure time [min] 8.7 (7.0–12.5) 8.0 (6.9–12.6) 0.689 7.5 (5.0–10.0) 9.5 (7.0–14.9) 0.047
RA spasm 3 (18%) 4 (14%) 0.763 3 (20%) 4 (13%) 0.670
Number of catheters used 1.2 ± 0.5 1.4 ± 0.6 0.594 1.2 ± 0.4 1.4 ± 0.6 0.175
Presence of CAD 13 (77%) 20 (59%) 0.214 10 (67%) 23 (64%) 0.850
Baseline RA diameter [mm] 2.54 ± 0.42 2.46 ± 0.32 0.442 2.63 ± 0.35 2.43 ± 0.35 0.056
Baseline FMD [%] 6.0 ± 4.4 18.8 ± 10.7 < 0.001 8.4 ± 6.8 19.6 ± 11.2 < 0.001
Baseline NMD [%] 10.3 ± 10.2 13.1 ± 12.2 0.425 4.0 ± 3.5 15.5 ± 12.0 0.007
CAD — coronary artery disease; FMD — flow mediated dilation; HDL — high density lipoproteins; LDL — low density lipoproteins;  
NMD — nitrate mediated dilation; PCI — percutaneous coronary intervention; RA — radial artery; RAS — renin–angiotensin system
Figure 3. Comparison of change in flow mediated dila-
tion (FMD) according to renin–angiotensin system (RAS) 
inhibitor use.
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Absolute change in FMD was significantly differ-
ent in patients using a RAS inhibitor compared to 
those who were not (1.9 ± 12.9% vs. –7.7 ± 12.7%, 
respectively, p = 0.025). However, it must be noted 
that baseline FMD of patients using a RAS inhibitor 
was already lower than other patients (4.3 [0–10.3] 
vs. 16 [12.0–19.3] %, p = 0.002) which may be re-
lated to higher incidence of hypertension (71.4 vs. 
29.7%, p = 0.007). While FMD of patients on RAS 
inhibitors did not change significantly after 1 week 
(4.3 [0–10.3] vs. 10.3 [5.2–16.4] %, p = 0.507), 
other patients experienced a significant reduction 
in FMD (16 [12.0–19.3] vs. 10.2 [3.4–15.7] %, 
p = 0.002).
Discussion
In our study of consecutive patients undergoing 
elective transradial procedure, we have confirmed 
that vasodilatory functions of RA were impaired 
after the procedure. However, functional impair-
ment did not develop in all the patients. Actually, 
approximately two thirds of patients have shown 
impaired vasodilation whether it be assessed with 
FMD or NMD. More strikingly, only 55% of patients 
have shown impairment in both FMD and NMD. 
That means that not all patients were functionally 
impaired after transradial procedure, although we 
re-assessed patients at 1 week by which time some 
functional recovery might have occurred.
Flow mediated vasodilation is mediated by 
endothelium-derived nitric oxide in response to 
shear stress and is a measure of endothelial func-
tion. Endothelial dysfunction of RA possibly results 
from endothelial denudation injury as induced in 
animal models [15]. Complete or incomplete recov-
ery of endothelial dysfunction is expected from as 
early as 24 h [16] up to 14 months after procedure 
[6, 9, 12, 17] although persistent impairment of 
RA function has also been reported [7, 10, 11, 13].
The major finding of our study was that deteri-
oration of endothelial function following transradial 
catheterization was alleviated with the use of RAS 
inhibitors. ACEIs and ARBs improve endothelial 
function by inhibiting production of angiotensin II 
and downstream blockade of angiotensin II type 1 
receptor, respectively. Angiotensin II plays a vital 
role in vasodilation [18]. By binding to type 1 
receptor, angiotensin II leads to vasoconstriction, 
endothelial cell migration, proliferation and hy-
pertrophy, increased uptake and oxidation of low 
density lipoprotein by endothelial cells and oxyradi-
cal production leading to endothelial dysfunction 
[19]. Additionally, increased bradykinin associated 
with angiotensin II inhibition increases the produc-
tion and release of nitric oxide, prostacyclin and 
endothelium-derived hyperpolarizing factor via 
binding to B2 receptors [20–22). Both ACEIs and 
ARBs significantly improve endothelial dysfunc-
tion, determined by FMD, compared to placebo 
or other anti-hypertensive agents as reported by 
meta-analyses [23, 24], and difference between 
ACEIs and ARBs is not statistically significant. 
Our study was the first to report the benefits of 
RAS blockade in RA injury following transradial 
catheterization. Considering that hypertension 
is frequent in the general population and there 
is evidence-based benefit for ACEI therapy in 
patients with stable coronary artery disease even 
without hypertension, diabetes, left ventricular 
systolic dysfunction or chronic kidney disease 
[25], RAS blockade can have a clinical application 
in transradial approach. Having said that, un-
less RAS blockade is systematically studied with 
a randomized controlled trial in transradial ap-
proach, conclusion about its protective role should 
be noted with caution. That is due to the fact that 
we have also found that patients on RAS inhibi-
tor therapy had lower baseline FMD compared to 
others which might be related to higher incidence 
of hypertension or undetected factors. As stated 
earlier, transradial catheterization impaired FMD 
of RA more severely in patients with higher base-
line values than in patients with somewhat lower 
baseline values, expectedly. Therefore, benefit of 
RAS blockade may not be applicable to all patients.
Nitrate mediated vasodilation, on the other 
hand, is mediated by exogenous nitric oxide donor 
and is a measure of endothelium-independent vaso-
dilation which is related to smooth muscle compo-
nent of arterial system. Transradial catheterization 
disrupted NMD with a similar extent to FMD in our 
study. This effect on NMD has been consistently 
observed in previous studies as well [9–12], which 
means that transradial procedures traumatize not 
only endothelial layer but arterial wall as a whole. 
RA diameter and potential procedure time were 
associated with NMD impairment in this study. 
A similar finding has been reported recently, where 
pre-procedural RA diameter to sheath size ratio 
predicted NMD reduction, albeit after 6 months 
[11]. Approximately 71% of participants had RA 
diameter smaller than outer diameter of 6 F sheath 
in our study, so mechanical sheath injury was highly 
likely. Longer duration of exposure to a sheath 
larger than its internal diameter was obviously 
associated with impaired NMD of RA. As only 6 F 
sheath was used in our study, we could not evaluate 
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the effect of sheath size. However, based on our 
findings and previous studies, downsizing transra-
dial equipment as safely as possible will clearly be 
a sensible choice for the prevention of RA injury.
Importantly, transradial catheterization causes 
an increase in RA diameter in acute phase which 
can be explained by direct mechanical (dilating) 
injury to arterial wall. Like in balloon angioplasty, 
damage induced by dilation of RA may trigger the 
events that lead to intimal hyperplasia and vascular 
remodeling [26]. Observed in our study, as well as 
in a previous one [9], this fact actually constitutes 
a limitation to FMD and NMD calculations because 
increase in baseline RA diameter early after pro-
cedure inevitably decreases the proportion of the 
same absolute increase in diameter with exogenous 
stimuli.
Limitations of the study
Important limitations were discussed previ-
ously. Others are acknowledged here. Obviously, 
a larger study population could have revealed other 
possible predictors, such as hypertension, coronary 
artery disease, number of catheter changes, etc. 
Additionally, long-term ultrasound examination 
could find out the incidence of persistent injury or 
further recovery of vasodilatory function, if any. 
However, long-term effects of sheath injury are 
controversial and dependent on the time of assess-
ment after procedure, as discussed previously [6].
Conclusions
Vasodilatory function of RA gets impaired in 
most patients early after transradial procedure. 
RAS blockade seems to exert a protective role 
against deteriorating endothelium-dependent 
vasodilation, whereas smaller RA diameter and po-
tentially longer procedure time are associated with 
impaired endothelium-independent vasodilation.
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